How LDL Targets Are Set in the 2026 Cholesterol Guideline

A single LDL-cholesterol number is not "good" or "bad" on its own. The 2026 ACC/AHA dyslipidemia guideline, released March 13, 2026, sets three LDL goals that depend on how much cardiovascular risk a person already carries: below 100 mg/dL for borderline-to-intermediate-risk primary prevention, below 70 mg/dL for high risk, and below 55 mg/dL for very-high-risk secondary prevention. The interesting question is not what the numbers are but where they came from, because each one is a compressed summary of what happened in randomized trials when LDL was driven lower.

Key points#

• LDL goals in the 2026 guideline are tiered by estimated risk: below 100, below 70, and below 55 mg/dL.
• The same drop in LDL buys roughly the same percentage risk reduction in almost everyone, so who benefits most in absolute terms depends on baseline risk.
• The guideline now estimates risk with the PREVENT equations instead of the older Pooled Cohort Equations.
• Treatment climbs a ladder ordered by evidence, tolerability, and cost: statin, then ezetimibe or bempedoic acid, then a PCSK9 agent.

The one finding that explains all three numbers#

Start with the result that every modern lipid guideline is built on. The Cholesterol Treatment Trialists' Collaboration pooled individual data from many large statin trials and found a remarkably steady pattern: for each roughly 1 mmol/L (about 39 mg/dL) fall in LDL, major vascular events dropped by about a fifth. That proportional benefit held up across people with and without diabetes, across ages, across both sexes, and across a wide span of starting risk.

Read that sentence twice, because it has a counterintuitive consequence. If the percentage benefit is nearly constant, then the value of treatment lives entirely in a person's underlying risk. Cut a large risk by a fifth and you prevent many events; cut a small risk by a fifth and you prevent few. Think of it like a discount: 20 percent off is meaningful on an expensive purchase and trivial on a cheap one. Risk stratification is simply the guideline's method for aiming the strongest LDL lowering at the people whose "purchase" is largest.

Why a low cholesterol reading is not the whole story#

This is why two people with an identical LDL can get different advice. One might be a healthy 40-year-old with no other risk factors; the other might have already had a heart attack. The same LDL sits on very different absolute-risk baselines, so the goal, and the effort worth spending to reach it, differ. The guideline encodes that by sorting people into tiers first, then attaching a target to each tier.

How the 2026 guideline estimates risk#

To place people in those tiers, the 2026 guideline adopts the PREVENT equations to estimate 10-year and 30-year cardiovascular risk in adults roughly 30 to 79 years old, retiring the older Pooled Cohort Equations. The change matters because the earlier equations tended to overestimate 10-year risk in current populations, nudging some people toward treatment their true risk did not warrant. Because recalibrating the estimate moves people across the treatment lines, the choice of risk equation is itself part of how a target is applied. Under PREVENT, LDL-lowering therapy becomes reasonable at borderline 10-year risk (about 3 to under 5 percent) and is recommended after a shared discussion at intermediate risk (about 5 to under 10 percent).

Where the lower two targets earned their evidence#

The three thresholds do not rest on one experiment; they climb through progressively harder tests.

The below-70 mg/dL goal for high-risk patients comes from trials of more intensive statin therapy. Pushing LDL below what standard doses achieved delivered additional event reduction, and the proportional relationship held at lower values.

The below-55 mg/dL goal for very-high-risk secondary prevention needed a further demonstration: that going lower still helps and that the benefit tracks the LDL number rather than any single drug. Two lines of evidence anchor it. IMPROVE-IT added ezetimibe to a statin and produced a modest but real further drop in events, important because ezetimibe works by a different mechanism, which argued that the achieved LDL, not the drug class, was doing the work. The PCSK9 inhibitor outcomes trials then extended the same logic to much lower LDL. In ODYSSEY Outcomes, alirocumab on top of intensive statin therapy in patients after acute coronary syndrome lowered LDL substantially and reduced recurrent events, and FOURIER showed a matching pattern with evolocumab. Newer outcomes data cited in the guideline continue to support intensive lowering toward the below-55 mg/dL range. Together they show the benefit curve keeps bending downward well past the LDL levels statins alone usually reach.

The treatment cascade is a ladder, not a staircase#

The familiar order, statin first, then ezetimibe or bempedoic acid, then a PCSK9 monoclonal antibody or inclisiran, is best understood as a ranking by evidence strength, tolerability, and cost, not a rigid protocol. Statins sit at the base because they hold the largest and longest outcomes record and cost little. Ezetimibe and bempedoic acid are oral, generally well tolerated, and backed by outcomes data, which makes them sensible next steps when a statin alone falls short of goal.

A notable 2026 change is structural. Ezetimibe is no longer a required stop before a PCSK9 monoclonal antibody, and bempedoic acid joins the menu of add-ons. That reflects a move away from a fixed staircase toward matching the size of the remaining LDL gap, and the patient's risk, to the potency of the next agent. Someone far above goal with very high risk may reasonably move to a potent injectable sooner. The guideline also raises the profile of measuring lipoprotein(a) at least once, and of using apolipoprotein B and selective coronary artery calcium scoring, to refine where a person sits before the ladder is climbed.

A guideline is a translation, not a command#

The cleanest way to read all of this is that a guideline converts a smooth biological relationship, lower LDL means proportionally lower risk, into a small set of thresholds and steps people can act on. Every printed number carries a buried judgment about the point where added benefit justifies added cost, burden, or uncertainty. Seeing the below-55, below-70, and below-100 mg/dL goals as calibrated summaries of trial evidence, applied through a risk estimate, is what makes them legible, and explains why the same LDL result can be a fine stopping point for one person and a reason to escalate for another.